Posters

Specific corneal changes in patients with keratitis of cytomegalovirus origin

Poster Details

First Author: A.Loshkareva RUSSIA

Co Author(s):    D. Mauchuk                    

Abstract Details

Purpose:

To show the common clinical features of chronic superficial Cytomegalovirus keratitis.

Setting:

Therapeutic Ophthalmology Department. Svyatoslav Fyodorov State Institution Eye Microsurgery Complex, 59A Beskudnikovskii Blvd, 127486, Moscow, Russia.

Methods:

120 patients were involved in the study. All patients had a history of one-side recurrent keratitis. Etiology was confirmed by the immunosorbent immunoglobulins M, G assay and polymerase chain reaction for Herpes Simplex Virus and Cytomegalovirus. PCR results were positive in 83 patients and correlated with specific clinical features. 16 patients had isolated Cytomegalovirus infection, 20 patients had equal titers between HSV 1,2 and Cytomegalovirus and 47 patients showed the prevalence of Cytomegalovirus titers. Method of treatment for all patients included Gancyclovir 0,15% and Valcyclovir pills 500mg. by standard scheme in the combination with anti-inflammatory and reparative treatment.

Results:

Clinical signs of Cytomegalovirus superficial corneal lesions observed: several non connected lesions in different sectors, correlating with a history of recurrence (71%). Prevailing superficial corneal localization, often with an endothelium edema in the same zone (58%). Development of primary inflammation in the deeper layers of the epithelium does not necessarily lead to the erosion, which occurs in 36% cases. Pigment deposition in the epithelized lesion area is seen often (44%), the neovascularization formation of one or several aggressive large central vessels, going into the affected zone is one of the most common findings (84%).

Conclusions:

Dominant role of Cytomegalovirus nature in the studied group of patients with unusual clinical picture was shown. This supports the empirical choice of full-spectrum antiviral therapy at the start of  superficial corneal lesions treatment.

Financial Disclosure:

None